Accueil>>Signaling Pathways>> Tyrosine Kinase>> DYRK>>DYRKs-IN-1 hydrochloride

DYRKs-IN-1 hydrochloride

Catalog No.GC62947

Le chlorhydrate de DYRKs-IN-1 est un puissant inhibiteur des DYRKs (kinases régulées par la tyrosine-phosphorylation À double spécificité) avec des CI50 de 5 nM et 8 nM pour DYRK1A et DYRK1B, respectivement. Le chlorhydrate de DYRKs-IN-1 a une activité antitumorale.

Products are for research use only. Not for human use. We do not sell to patients.

DYRKs-IN-1 hydrochloride Chemical Structure

Cas No.: 1386980-55-7

Taille Prix Stock Qté
5 mg
680,00 $US
En stock
10 mg
1 080,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity[1][2].

DYRKs-IN-1 hydrochloride (compound 30) increases the cellular potency against the human colon tumor cell line SW 620 with an EC50 of 27 nM[1]. DYRKs-IN-1 hydrochloride (Example 183) is a potent DYRKs inhibitor[2].

[1]. Anderson K, et al. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6610-5.
[2]. Kevin Anderson, et al. Pyrido pyrimidines. US20120184542A1.

Avis

Review for DYRKs-IN-1 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for DYRKs-IN-1 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.